Last reviewed · How we verify
NCT04456972
Reliability and Interest of Circulating Tumor DNA in Endometrial Cancers.
NA trial testing One arm only in Circulating Tumor DNA in 44 participants. Completed in 8 January 2022.
8 January 2022
Quick facts
| Lead sponsor | Poitiers University Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 44 |
| Start date | 19 June 2020 |
| Primary completion | 8 January 2022 |
| Estimated completion | 8 January 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- One arm only
Conditions studied
- Circulating Tumor DNA — all drugs for Circulating Tumor DNA →
- Endometrial Cancer — all drugs for Endometrial Cancer →
Sponsor
Poitiers University Hospital
Who can join
18 and older, female only, with Circulating Tumor DNA or Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The recent histo-prognostic molecular discoveries of the TCGA (The Cancer Genome Atlas) have shed new light on the classification of endometrial carcinomas. After carrying out different types of high-throughput molecular analyzes on 373 endometrial carcinomas of different histological types, 4 major tumor subtypes could be identified, each with a different survival profile (the "ultra-mutated" group with POLE mutations, the "hypermuted" group with microsatellite instability (MSI), the "low number of copies" group, and the "high number of copies" group). This histomolecular classification is not yet directly transposable to clinical practice and tumor genetic characteristics have not had any direct therapeutic impact to date. The main objective of the study is to determine the concordance rate between molecular analysis of tumor tissue and that of cDNA in patients with endometrial cancer during treatment.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Liquid Biopsy for Monitoring EC Patients: Towards Personalized Treatment.
Piñeiro-Pérez R, Abal M, Muinelo-Romay L. · · 2022 · cited 7× · PMID 35326558 · DOI 10.3390/cancers14061405 -
Beyond the Microscope: Integrating Liquid Biopsies into the Molecular Pathology Era of Endometrial Cancer.
Perez M, Carvajal LL, Wong A, Poppiti R, et al · · 2025 · PMID 40869308 · DOI 10.3390/ijms26167987
Verify or expand the search:
- PubMed search for NCT04456972
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Circulating Tumor DNA
Currently open trials in the same condition.
- NCT06495554 — Danish Vulva Cancer Recurrence Study · NA · recruiting
- NCT06479460 — Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients · recruiting
- NCT05787197 — ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases · recruiting
- NCT05601505 — Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer · Phase 2 · recruiting
- NCT06707519 — NSCLC Liquid Biopsies and Exhaled VOC · recruiting
Other Poitiers University Hospital trials
Trials by the same sponsor.
- NCT07350291 — Evaluation of the Diagnostic Capabilities of Saliva Samples From Pediatric Patients, Promoting Active Involvement of the · NA · not yet recruiting
- NCT07411651 — Confirmation of the Link Between Endocrine Disruptors Exposure and Breast Cancer and Identification of Biological Respon · NA · not yet recruiting
- NCT07463963 — Relevance of the Urine Bacterial Culture Performed Before TransUrethral Resection of the Bladder for Post-operative Febr · NA · not yet recruiting
- NCT07475442 — Prognostic Factors of Hospitalization for Patients Aged 75 and Over in Emergency Department in France - Monocentric Retr · not yet recruiting
- NCT07412717 — The Efficacy of Combining Music Intervention With Nicotine Replacement Therapy to Reduce Smoking Craving, Among Healthca · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04456972 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Poitiers University Hospital
- Last refreshed: 4 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04456972.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing